INOZYME PHARMA, INC.

Insiders Inozyme Pharma, Inc.

Equities

INZY

US45790W1080

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
4.46 ^USD	-1.33%		+0.22%	+4.69%

05-30	Wells Fargo Starts Inozyme Pharma With Overweight Rating, $14 Price Target	MT
05-16	Transcript : Inozyme Pharma, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:40 PM

Insiders

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Insider Buy: Inozyme Pharma	04/08/23	MT
Insider Buy: Inozyme Pharma	15/05/23	MT
Insider Buy: Inozyme Pharma	30/03/23	MT
Inozyme Pharma, Inc. Announces Management Changes	22/03/23	CI
Inozyme Pharma, Inc. Announces CEO Changes	22/03/23	CI
Inozyme Pharma, Inc. Announces Resignation of Henric Bjarke as Senior Vice President and Chief Operating Officer of the Company	08/12/22	CI
Inozyme Pharma, Inc. Appoints Kurt Gunter as Chief Medical Officer	07/06/22	CI
Insider Buy: Inozyme Pharma	21/04/22	MT
Inozyme Pharma Appoints Former Ocugen Finance Chief Sanjay Subramanian in Same Role	08/03/22	MT
Inozyme Pharma, Inc. Announces Management Changes	08/03/22	CI
Inozyme Pharma, Inc. Announces Appointment of Gayle Gironda as Senior Vice President of Human Resources	13/07/21	CI
Inozyme Pharma, Inc. Announces the Resignation of Stephen Basso as Senior Vice President, Finance, Effective May 14, 2021	21/04/21	CI
Inozyme Pharma Announces Executive Changes	01/04/21	CI
Inozyme Pharma Announces Executive Changes	04/02/21	CI
Inozyme Pharma Appoints Kevin B. Johnson as Senior Vice President, Regulatory Affairs	09/11/20	CI
Inozyme Pharma, Inc. Announces Executive Changes	13/10/20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer